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Abstract
Estrogens, GH and IGFs are essential in the development and growth of the skeleton and for the main-
tenance of bone mass and density. Treatment of precocious puberty with GnRH analogs (GnRHa), by
reducing sex steroid levels, leads to a situation of hypoestrogenism that may theoretically have a det-
rimental effect on bone mass during pubertal development. A reduction in bone mineral density
(BMD) during GnRHa treatment has been demonstrated, but GnRHa treatment in patients with cen-
tral precocious puberty (CPP) does not seem to impair the achievement of normal peak bone mass
(PBM) at final height. However, calcium supplementation is effective in improving bone densitometric
levels and may promote better PBM achievement. In children and adolescents with GH deficiency
(GHD), BMD assessed by dual-energy X-ray absorptiometry (DEXA) and bone turnover are signifi-
cantly reduced, but they are stimulated by GH treatment. GH treatment leads to improved bone den-
sity, function of the dose and duration of treatment, and patients may require prolonged GH treatment
beyond the time of growth to improve PBM. After the discontinuation of GH therapy, the more active
population had higher bone mineral content (BMC) levels than patients with low physical activity. In
our experience, the therapeutic association of GH and calcium also represents a valuable tool in pur-
suing a proper BMC in GHD patients. We concluded that nonhormonal factors, such as physical
activity and nutritional factors, are important in determining bone metabolism and bone mass.
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Introduction
Normal bone mineral accretion during childhood and
adolescence is a complex process involving genetic deter-
minants, growth hormone (GH)/insulin-like growth
factor (IGF)-I effects, gonadal steroids, and nutritional
and other environmental factors, such as physical
activity (1). In healthy subjects, bone mass increases
throughout childhood, withmaximal bonemass accrual
occurring in early to middle puberty and slowing in late
puberty, reaching peak bone mass (PBM), defined as
maximal bone mineral density (BMD) (2). About half of
the adult PBM is accumulated during the adolescent
growth spurt (3–4). The precise age at which PBM is
reached is both method- and site-dependent. Most of
the lumbar and femoral BMD is achieved around
14.5–16.0 years in girls and 16.5–18.0 years in boys
(5–8). Lumbar BMD continues to increase after the com-
pletion of growth, achieving PBM 1–2 years later (4, 9).
The magnitude of PBM achieved depends not only on
genetic potential (race, sex and heredity) (10), but also
on nutritional factors (calcium intake) (11, 12), dis-
orders in timing of puberty (3), hormonal deficiency or
pharmacologic treatments, and environmental factors
as well as physical activity (13, 14).
Estrogens play an important role in skeletal matu-
ration and mineralization and in the relevant increases
in bone mass observed during puberty (15). Even at low
levels, they promote normal skeletal growth and bone
maturation in boys as well as girls, increasing and
maintaining BMD (16), and controlling bone turnover
rate (17). Hypoestrogenic conditions, such as natural
menopause and GnRH analogs (GnRHa) adminis-
tration in premenopausal women (18, 19), are charac-
terized by bone mass reduction. Patients with
aromatase deficiency or estrogen-receptor defects have
a phenotype that includes tall stature and normal sec-
ondary sexual characteristics. These patients have
osteoporosis and skeletal immaturity in adulthood
despite normal androgen levels (20), with a dramatic
improvement in bone density and completion of skeletal
maturation after estrogen treatment (21).
GH and IGF are essential in the development and
growth of the skeleton and for the maintenance of
bone mass and density (22). Levels of GH and IGF-I
increase dramatically during normal puberty, aug-
mented by increasing levels of sex steroids. Much of
the GH action on bone is mediated through IGF-I,
which acts in an endocrine and autocrine/paracrine
manner as a bone-trophic hormone that positively
affects bone growth and bone turnover by stimulat-
ing osteoblasts, collagen synthesis and longitudinal
bone growth (23).
In this review we will discuss particularly bone devel-
opment in two situations: central precocious puberty
(CPP) treated by GnRHa and GH deficiency (GHD) in
children and adolescents before, during and after GH
treatment.
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Central precocious puberty (CPP)
The spinal BMD of patients with untreated precocious
puberty has been reported to be high for chronologic
age (CA) (24) but appropriate for advanced bone age
(BA) (25–27), or, in one study, to be lower than the
normal mean for BA (28), probably because bone matu-
ration and bone mineralization do not necessarily
advance simultaneously (29).
Treatment of precocious puberty with GnRHa, by
suppressing gonadotropin secretion and reducing sex
steroid levels, leads to hypoestrogenism, which may
be accompanied by delayed skeletal maturation and
deficient bone mineralization (25, 26). This estrogen
deprivation may theoretically have a detrimental
effect on bone mass during pubertal development.
CPP during treatment with GnRHa
To test this hypothesis, we studied some years ago (26)
bone mineral metabolism and mineralization by dual-
energy X-ray absorptiometry (DEXA) before and
during treatment in 10 girls aged 6.9–8.4 years
affected by CPP and treated with GnRHa, in order to
clarify the consequences of estrogen deficiency and of
the reduction of GH–IGF-I axis activity.
During treatment, a decrease of serum estradiol
levels from pubertal to prepubertal levels was observed.
The GH peak following clonidine significantly dimin-
ished after 1 year. IGF-I and insulin-like growth
factor-binding protein (IGFBP)-3 decreased, though
not significantly. Osteocalcin levels, at pubertal range
before therapy, decreased to prepubertal levels after 9
and 12 months of treatment, consistently with the
arrest of pubertal development, when growth slowed
following therapy (30). Urinary hydroxyproline, a
marker of bone resorption, significantly decreased
after 12 months. Before therapy, lumbar spine and
radius bone mass were high for CA, but appropriate
for BA; after 12 months of treatment, bone mass in
the lumbar spine, but not in the radius, decreased sig-
nificantly. These changes in bone density may indicate
that the initial event, as a consequence of treatment of
CPP, is a suppression of bone formation. In our patients,
GnRHa administration negatively affected both cortical
and trabecular bone, in accordance with another
report (25). Cortical bone is less sensitive to rapid
changes in bone metabolism, and the rate of bone
loss is much lower than that of trabecular bone. The
bone loss measured by lateral DEXA, excluding from
analysis the posterior portions of the vertebrae
(mainly cortical bone), was, in fact, twofold higher
than in anteroposterior (AP) scans. When DEXA is
used in growing children, an increase of bone size
alone induces an increase in photon absorption.
When corrected for the volume (vBMD), bone mass sig-
nificantly decreased. The decline in estrogen levels is
associated with increased turnover and bone loss in
adult women, but, in the present study, bone turnover
diminished. The bone loss we observed can be explained
only by an uncoupling between bone resorption and
bone formation. Reduced bone formation is the primary
consequence of GnRHa therapy, and this could possibly
be related to decreased GH secretion. After the initial
reduction of bone formation, there could be, after a
few months, a comparable decrease in bone resorption,
with consequent transient bone loss.
A reduction in BMD during GnRHa treatment has
been demonstrated in other studies (25), although in
one study BMD values increased, and the BMD S.D.
score for age and skeletal age did not change during
treatment (27). It is obvious that, at such a critical
age, a decrease in BMD, instead of an increase as
expected in normal growing girls, might have a nega-
tive impact on PBM and produce a higher risk of post-
menopausal osteoporosis. At that time, we stated that
this reduction is possibly entirely reversible, as proven
in premenopausal women treated with GnRHa (18).
CPP at the end of GnRHa treatment
In a previous study on girls affected by CPP, we demon-
strated that BMD reduction during GnRHa therapy was
reversible and preventable by providing calcium sup-
plementation from the beginning of treatment (31).
To determine whether GnRHa treatment impaired
the achievement of an adequate bone mass at growth
completion and whether calcium supplementation
improved bone mass in patients treated with GnRHa,
we conducted a longitudinal study (32) to evaluate
bone mass after long-term GnRHa therapy with or
without calcium supplementation in females affected
by CPP who had reached final height. In fact, it was
demonstrated that calcium intake correlates with
bone density in healthy children and adolescents (33),
and that calcium supplementation above the rec-
ommended dietary allowances increases bone density
in children (34).
We studied 48 Caucasian females affected by CPP
(age at diagnosis, 7.19^0.96 years), randomly
assigned to two groups: group A (n ¼ 21) treated
with GnRHa and group B (n ¼ 27) treated with
GnRHa plus calcium gluconolactate and carbonate
(1 g calcium/day in two doses) for at least 2 years.
Auxologic parameters (standing height, weight, body
mass index) and BMD at the lumbar spine (L2–L4,
anteroposterior (AP)–BMD; lateral BMD; and volu-
metric (vBMD)), total BMC (TBMC) and total BMD
(TBMD), by DEXA were evaluated at the beginning, at
the end of treatment and at final height.
The vBMD was significantly higher in group B than
in group A at the end of the treatment period and at
final evaluation (P , 0.05). The percent change (D%)
between the start and end of treatment period in AP–
BMD and vBMD was significantly higher in group B
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than in group A and also between the start of treat-
ment and final evaluation (Table 1).
In all our females with CPP (both groups A and B) at
final evaluation, treated with GnRHa, bone densito-
metric parameters (final TBMC, TBMD, AP–BMD L2–
L4 and vBMD) were in the normal range for age and
sex, even if lower than in controls, but the differences
were not statistically significant (Fig. 1). Therefore, in
our study, as in other studies (35–38), GnRHa treat-
ment in patients with CPP does not seem to impair
the achievement of normal PBM. In calcium-sup-
plemented patients, vBMD levels at the end of therapy
and final evaluation were significantly higher than in
patients treated only with GnRHa. Moreover, D% AP-
BMD and D% vBMD between the beginning of treat-
ment and final evaluation were also significantly
higher in calcium-supplemented patients than in
patients treated only with GnRHa, with a significant
relationship with the duration of calcium supplemen-
tation. Thus, calcium supplementation is effective in
improving bone densitometric levels and may preserve
better PBM achievement (32).
A limitation of the study is that, as well known, PBM
is not achieved at final height but later in life (2).
Therefore, the effect of precocious puberty and its treat-
ment on PBM should be re-evaluated later, at approxi-
mately 20–30 years of age.
Probably the majority of the general population do
not require calcium supplementation because of good
genetic background, adequate diet, and good physical
activity. But in some individuals, such as patients trea-
ted with drugs that potentially interfere with bone min-
eral metabolism, it is probably better to increase
calcium intake (2).
GnRHa treatment outside CPP
In a randomized clinical trial, treatment with GnRHago-
nist was used to increase adult height in adolescentswith
short stature and normally timed puberty (39). In this
study, the principal adverse event in the GnRH-agonist
group was reduced lumbosacral BMD during treatment
and inadequate catch-up accretion of bone mineral
after treatment (mean lumbar vertebral BMD at the
time adult height was achieved, 1.6^1.2 S.D. below
population mean, vs 0.3^1.2 S.D. below population
mean in the placebo group; P , 0.001). Due to this
adverse effect, the authors stated that such treatment
cannot be routinely recommended to augment height
in adolescents with normally timed puberty.
GH deficiency (GHD)
In children and adolescents with GHD, BMD assessed by
DEXA and bone turnover are significantly reduced (40),
reflecting decreased bone modeling and remodeling
(41), because of delayed bone maturation or absence
of GH anabolic activity (42).
Reduced BMD detected by DEXA is commonly
reported in untreated adult patients with childhood
(43, 44) or adult onset GHD (45–46) (the former show-
ing more pronounced effects of GHD on bone mass than
the latter), with respect to normal controls and treated
patients, and one-third of patients had lumbar bone
density 2 S.D. or more below the normal mean (48).
Reduced BMD by DEXA in GHD adults may be
explained either by a failure to achieve normal PBM
or by subsequent bone loss during adult life (45, 46),
and the severity of bone loss is proportional to the bio-
chemical severity of GHD (49).
However, DEXA provides an areal density measure-
ment rather than a true volumetric density, and low
bone density measurements may reflect reduced
height and thus bone size in these patients. When
bone density is measured by peripheral quantitative
computed tomography (pQCT) or estimated by calcu-
lated methods from DEXA measurements to correct
for bone size (vBMD), spinal bone density is still reported
as reduced if compared with age- and sex-matched
reference data (50, 51). However, in recent studies,
Table 1 Chronologic age (CA) and bone age (BA) of patients at various times of evaluation: densitometric values (volumetric bone
mineral density–vBMD), D% AP–BMD and D% vBMD between the start and end of treatment (start–stop), end of treatment and final
evaluation (stop–final), and the start of treatment and final evaluation (start–final).
Start of treatment End of treatment Final evaluation
CA 7.3^0.9 11.3^0.97 16.2^1.9
BA 8.80^1.24 12.35^0.43 16.93^0.98*
vBMD g/cm3 group A 0.175^0.016 0.192^0.021 0.227^0.024
group B 0.177^0.014 0.213^0.022a 0.246^0.023b
Start–end of treatment End of treatment–final evaluation Start of treatment–final evaluation
D% AP–BMD group A 16.16^1.90 40.81^2.45 56.97^1.45
group B 20.36^1.10a 40.87^3.32 61.23^1.61a
D% vBMD group A 9.26^5.15 17.18^3.05 28.01^5.76
group B 19.08^3.52a 14.81^3.08 36.69^5.01a
* In each case .15 years.
aP , 0.01 vs group A.
bP , 0.05 vs group A.
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pQCT showed that cortical bone density was not
reduced in GHD children (52), and vBMD was reported
as normal to near normal (mean Z scores: 21.2, þ0.8,
and þ0.8 for lumbar spine, femoral neck and total skel-
eton respectively) in patients with genetic growth hor-
mone-releasing hormone (GHRH)-receptor deficiency
(53). These reports stressed that GH/IGF-I deficiency
has relatively little impact on bone mineralization
during the bone accretion phase, in marked contrast
to its effect on bone elongation and overall bone size.
Adult-onset GHD patients have a threefold increase
in fracture risk compared with the general population
(54), and it was recently demonstrated that children
with GHD had an approximately fourfold decreased
fracture frequency from diagnosis up to final height
compared with controls (61).
GH treatment
GH treatment in GHD children stimulates bone turn-
over (40–42) and improves BMD (42, 55–58).
In treated GHD children, an increase in lumbar bone
density by DEXA after 6 months of treatment, but no
significant change in calculated vBMD until after 2
years of treatment, was reported. Early changes in
bone density measurements may reflect changes in
bone size, but prolonged treatment results in improve-
ment in net bone formation (42). Longitudinal data
in GHD children treated for an average of 4 years
demonstrated a significant improvement in radial and
lumbar bone density. The greatest improvement was
observed with the longest treatment duration, with
z-scores approaching mean reference values (58).
At final height, normal (60, 61) or reduced (62)
mean values of lumbar BMD were found in GH-treated
GHD patients. Approximately 20% of GHD children
treated with GH had a value of lumbar BMD between
21 and 22 S.D. of the normal mean at final height,
with increased susceptibility to fractures during GH
treatment (61). Reduced lumbar BMD was found expe-
cially in patients with GHD who had received inter-
rupted and low-dose GH treatment during the period
of pituitary-derived GH during childhood (44, 59),
but it has been shown that there was no difference in
lumbar BMD at final height between patients with
GHD who had received standard (0.3mg/kg per week)
or high GH dosage (0.7mg/kg per week) (62).
In patients with GHD, increased lumbar BMD after the
attainment of final height has been found 2 years (60)
after discontinuation of GH treatment. GH-retreated
patients with childhood (63, 64) or adult (65) onset
GHD also had an increased BMD after discontinuation
of GH treatment that could be due to a persisting effect
of GH treatment inducing a bone-remodeling cycle,
which continues until the new bone is fully mineralized
(65).
In adolescents with GHD who normally discontinue
GH at completion of linear growth, BMD is substantially
lower than PBM for a young adult population. A recent
report on adolescents with GHD who continued GH
administration after the completion of linear growth
showed an increased lumbar BMD after 12 months of
therapy, which was not observed in untreated patients
(66). Moreover, reinstitution of GH replacement after
final height in severely GH-deficient patients induced
significant progression toward PBM (67, 68).
All these data suggest that GH treatment leads to
improved bone density, according to the dose and dur-
ation of treatment, and that patients may require pro-
longed GH treatment beyond the time of growth to
improve PBM. Cessation of GH at achievement of final
height, by limiting PBM, may predispose to clinically
significant osteoporosis in later life, also by a super-
imposed accelerated loss of BMD with advancing age
similar to the situation observed in adult-onset GHD.
Pubertal GH-deficient patients treated with GH and
GnRHa had a significantly lower BMC after 3 years of
therapy. This difference, however, did not persist after
both groups of patients reached final height.
GH treatment and calcium
supplementation
We conducted a preliminary study to evaluate BMD
during GH therapy, with or without calcium
supplementation, to determine whether calcium sup-
plementation improved bone mass in patients treated
with GH and calcium.
Twelve prepubertal Caucasian GH-deficient patients
(seven females, five males), 5–14 years old, took part
in the study. The diagnosis of GHD was based on the
Figure 1 Central precocious puberty (CPP). Individual vBMD
levels at final evaluation in group A (GnRHa alone, white squares)
and group B (GnRHa and Ca, black circles). vBMD levels were
significantly higher in group B than in group A (P , 0.05).
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following criteria: height of #2 SDS; bone age delay of
.2 years compared with CA; peak GH of,10ng/ml in
at least two consecutive pharmacologic tests; reduced
IGF-I. None of the patients had organic GHD or multiple
pituitary hormone deficiency, all being affected by idio-
pathic isolated GHD, as assessed by full endocrine
evaluation and pituitary molecular resonance imagery
(MRI).
Patients, all treated with GH at a dose of 0.033mg/kg
per day 6 days a week, were randomly assigned to two
groups (A and B) comparable for age, BA weight and
height, using a computer pseudo-random number gen-
erator. Patients in group A (n ¼ 6) were treated solely
with GH; patients in group B (n ¼ 6) received GH plus
supplementation of calcium gluconolactate and carbon-
ate (1 g calcium/day per os in two doses).
No patients received other drugs known to interfere
with bone mineral metabolism. All the subjects were
instructed to continue their usual physical activity
and diet, thereby ensuring adequate caloric (70–
80 cal/kg per day), protein (.1 g/kg per day), calcium
(.800mg/day), and phosphate (.800mg/day) intake
during treatment. Diet and dietary calcium intake were
investigated by a weighed food record and exercise by
an exercise diary. Compliance with assumption of cal-
cium supplementation was checked by a diary.
At the start of therapy, the patients of groups A and B
were comparable for age, weight, height and body com-
position, BMC and bone turnover. The biochemical data
of bone turnover of patients of groups A and B after 12
months of treatment evidenced comparable values in
both groups. After 12 months of therapy, BMC signifi-
cantly increased in patients of group B, supplemented
with calcium, compared with those of group A treated
solely with GH (P , 0.05).
Therefore, in our experience, the therapeutic associ-
ation of GH and calcium represents a valuable tool in
pursuing not only the final target but also proper
BMC in GHD patients.
Physical activity at the end of GH
treatment
For better determination of body composition after dis-
continuation of GH therapy, we re-evaluated 20 young
men with GHD diagnosed in childhood that had com-
pleted pubertal development (age 18–20 years), 12
months after stopping therapy for at least 6 years
with GH at the dose of 0.6 IU/kg per week. The par-
ameters studied included final height, spontaneous
nocturnal GH secretion and body composition by
DEXA (Expert XL; Lunar Corp., Madison, WI, USA),
which enabled assessment of whole-body as well as
regional soft tissue composition. Re-evaluation of GH
secretion in these patients showed that 12 remained
GH deficient (persistent GHD) with abnormal spon-
taneous nocturnal GR secretion (11 multiple pituitary
deficiency and one isolated GHD), while eight recovered
normal somatotropic secretion (transient GHD). BMC
was positively influenced, as expected, by GR action.
GHD patients, 12 months after discontinuation of GH
therapy, had BMC levels very close to the control
group of normal young adults. One year after stopping
the GH treatment, patients with confirmed GHD
showed an increased fat mass as compared with the
value at the end of the treatment; in this group, we
divided patients into two distinct populations, on the
basis of exercise quantity. The more active population
had higher BMD levels, expecially at lumbar and thor-
acic spine than the patients with low physical activity
(Table 2) (69). We concluded that nonhormonal fac-
tors, such as physical activity and nutritional factors,
are important in determining bone metabolism and
bone mass.
Conclusions
Normal bone mineral accretion during childhood and
adolescence is a complex process involving genetic
determinants, GH/IGF-I effects, gonadal steroids, and
nutritional and other environmental factors, such as
physical activity. Estrogens, GR and IGFs are essential
in the development and growth of the skeleton and
for the maintenance of bone mass and density.
Treatment of precocious puberty with GnRHa, by
suppressing gonadotropin secretion and reducing sex
steroid levels, leads to a situation of hypoestrogenism,
which may theoretically have a detrimental effect on
bone mass during pubertal development. A reduction
in BMD during GnRHa treatment has been demon-
strated, but GnRHa treatment in patients with CPP
does not seem to impair the achievement of a normal
PBM at final height. However, calcium supplementation
is effective in improving bone densitometric levels and
may promote better PBM achievement.
In children and adolescents with GH deficiency, BMD
by DEXA and bone turnover are significantly reduced,
but are stimulated by GH treatment. At final height,
normal or reduced mean values of lumbar BMD were
found in GH-treated GHD patients. GH treatment
leads to improved bone density, function of the dose
Table 2 Bone mineral density (g/cm2) in GHD patients 12 months
after discontinuation of GH therapy, subdivided by physical
activity (high and low).
High Low
Number 7 5
Subtotal 1.082^0.043 0.870^0.037
Lumber spine 1.187^0.073 0.742^0.069
Thoracic spine 1.004^0.039 0.649^0.042
Left leg 1.288^0.086 1.056^0.065
Right leg 1.273^0.084 1.043^0.038
Left arm 0.787^0.024 0.673^0.033
Right arm 0.802^0.022 0.675^0.036
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and duration of treatment, and patients may require
prolonged GH treatment beyond the time of growth to
improve PBM. After the discontinuation of GH therapy,
the more active population had higher BMC levels than
patients with low physical activity. In our experience,
the therapeutic association of GH and calcium also rep-
resents a valuable tool in promoting proper BMC in
GHD patients.
We concluded that nonhormonal factors, such as
physical activity and nutritional factors, are important
in determining bone metabolism and bone mass.
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